The evolutionary safety of mutagenic drugs should be assessed before drug approval

• Gabriela Lobinska,

  Roles Writing – original draft, Writing – review & editing

  Affiliation Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

  https://orcid.org/0000-0001-7215-4111

  ⨯
• Vyacheslav Tretyachenko,

  Roles Writing – original draft, Writing – review & editing

  Affiliation Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

  ⨯
• Orna Dahan,

  Roles Writing – original draft, Writing – review & editing

  Affiliation Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

  ⨯
• Martin A. Nowak ,

  Roles Writing – original draft, Writing – review & editing

  * E-mail: martin_nowak@harvard.edu (MAN); pilpel@weizmann.ac.il (YP)

  Affiliation Department of Mathematics & Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, United States of America

  ⨯
• Yitzhak Pilpel

  Roles Writing – original draft, Writing – review & editing

  * E-mail: martin_nowak@harvard.edu (MAN); pilpel@weizmann.ac.il (YP)

  Affiliation Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

  https://orcid.org/0000-0003-3200-9344

  ⨯